Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Percheron Therapeutics (PERCF) Stock Price & Analysis

13 Followers

PERCF Stock Chart & Stats

$0.00$0.00(0.00%)
At close: 9:35 AM EDT
$0.01$0.0125$0.015$0.0175Aug 6Aug 26Oct 7
Day’s Range
$0.01 - $0.01
52-Week Range
$0.01 - $0.02
Previous Close
$0.01
Volume
N/A
Average Volume (3M)
3,333
Market Cap
$4.09M
Enterprise Value
-$1.17M
Total Cash (Recent Filing)
$4.05M
Total Debt (Recent Filing)
$27.79K
Price to Earnings (P/E)
―
Beta
0.76
Next Earnings
Feb 24, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage

Minimal debt reduces interest and refinancing pressure, giving Percheron greater financial flexibility as it advances its clinical programs. This limits balance-sheet risk, although it does not remove the need for funding while the company remains pre-commercial.

Improved Cash Outflow

The reduction in cash outflow indicates some improvement in near-term cost management and cash preservation. If sustained, this could extend the company’s funding runway and support continued development activity while it works toward clinical and regulatory milestones.

Focused Clinical Development Platform

A focused pipeline in serious neurological and neuromuscular diseases provides a defined strategic direction and potential access to high-need markets. Continued clinical and regulatory progress could create long-term value if candidates demonstrate safety and efficacy.

Bears Say

No Revenue Base

The absence of revenue confirms that Percheron has not yet established a commercial product base or recurring operating income. This leaves results dependent on development progress and external capital until a candidate can be approved and commercialized.

Persistent Cash Burn

Recurring negative operating and free cash flow means the business consumes cash rather than funding itself. Unless revenue begins to materialize, continued clinical development will likely require additional financing, creating dilution and execution risk.

Sustained Losses And Equity Erosion

Persistent losses are reducing the capital base and weakening financial resilience despite low debt. The company remains far from breakeven, so prolonged development timelines or setbacks could accelerate equity erosion and increase reliance on external funding.

Percheron Therapeutics News

PERCF FAQ

What was Percheron Therapeutics’s price range in the past 12 months?
Percheron Therapeutics lowest stock price was $0.01 and its highest was $0.02 in the past 12 months.
What is Percheron Therapeutics’s market cap?
Percheron Therapeutics’s market cap is $4.09M.
When is Percheron Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Percheron Therapeutics’s earnings last quarter?
Percheron Therapeutics released its earnings results on Aug 19, 2026. The company reported -$0.001 earnings per share for the quarter.
Is Percheron Therapeutics overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Percheron Therapeutics pay dividends?
Percheron Therapeutics does not currently pay dividends.
What is Percheron Therapeutics’s EPS estimate?
Percheron Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Percheron Therapeutics have?
Percheron Therapeutics has 1,982,415,500 shares outstanding.
What happened to Percheron Therapeutics’s price movement after its last earnings report?
Percheron Therapeutics reported an EPS of -$0.001 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Percheron Therapeutics?
Currently, no hedge funds are holding shares in PERCF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology